A Safety and Biodistribution Study of [I-124]-CPD-1028 Injection in Solid Tumours

Phase 1

Completed

• Conditions: Cancer
• Interventions: Drug: [I-124]-CPD-1028 Injection; Biological: CPD-1061

• Registration Number: NCT02134340
• Lead Sponsor: Centre for Probe Development and Commercialization

Brief Summary

The purpose of the study is to evaluate the safety and biodistribution of \[I-124\]-CPD-1028 Injection in cancer patients with solid tumours.

Detailed Description

Up to 18 adult participants will be enrolled in this Phase 1a study to evaluate the safety and biodistribution of \[I-124\]-CPD-1028 Injection in patients with Insulin-like Growth Factor-1R (IGF-1R) upregulated solid tumours. All eligible subjects who have given written informed consent and qualify based on the study's inclusion/exclusion criteria will be enrolled in the study. Each enrolled subject will take part in six visits consisting of a screening visit, an Investigational Product administration visit, 3 assessment visits involving 2-3 Positron Emission Tomography/Computed Tomography (PET/CT) scans, and a follow-up safety telephone call. At Visit 2, subjects will start a course of treatment to protect the thyroid from radioactivity and may receive a pre-targeting dose of an additional investigational agent, CPD-1061.

Study Timeline

• Study First Submitted: 2014-04-14
• Study First Submitted QC: 2014-05-07
• Study First Posted: 2014-05-09
• Study Start: 2014-06
• Status Verified: 2016-04
• Primary Completion: 2016-06
• Study Completion: 2016-06
• Last Update Submitted: 2016-10-14
• Last Update Posted: 2016-10-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2

Inclusion Criteria

1. Age ≥18 years old with life expectancy > 12 weeks with confirmed metastatic or unresectable malignancy
2. Patients must have progressed after at least first-line chemotherapy and have an Eastern Cooperative Oncology Group (ECOG) status of 0, 1 or 2.
3. All patients must have archival tumour samples available and must have verification of IGF-1R expression.
4. Patients must have adequate organ and marrow function, vital signs and ECG.
5. Females of childbearing potential must not be pregnant and both males and females must use adequate forms of contraception.
6. Signed informed consent form
7. Subject must be compliant and have a high probability of completing the study.

Exclusion Criteria

1. Patients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from previous treatment.
2. Patients who have received a therapeutic radiopharmaceutical in the past year or who are currently receiving any other investigational agents.
3. Previous treatment with IGF-1R inhibitors.
4. Patients who are currently taking antithyroid medications and lithium or potassium sparing diuretics.
5. Subjects with known or suspected allergies or contraindications to the investigational agents and iodine
6. Subjects with uncontrolled intercurrent illness
7. Female subjects who are pregnant, planning to become pregnant or are lactating and/or breast-feeding.
8. Patients with diabetes requiring therapy unless controlled through diet or metformin.
9. Subjects who are undergoing monitoring of occupational ionising radiation exposure.
10. Subjects with hypothyroidism requiring thyroid supplementation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
[I-124]-CPD-1028 PET/CT	[I-124]-CPD-1028 Injection	Administration of \[I-124\]-CPD-1028 Injection followed by a maximum of 3 PET/CT imaging sessions. A pre-targeting dose of CPD-1061 may be given prior to injection of \[I-124\]-CPD-1028.
[I-124]-CPD-1028 PET/CT	CPD-1061	Administration of \[I-124\]-CPD-1028 Injection followed by a maximum of 3 PET/CT imaging sessions. A pre-targeting dose of CPD-1061 may be given prior to injection of \[I-124\]-CPD-1028.

Primary Outcome Measures

Name	Time	Method
Obtain preliminary biodistribution data for [I-124]-CPD-1028	Up to 18 days	Biodistribution data will be assessed by quantitative analysis of imaging scans taken 2-3 days and 5-7 days post injection by (1) measuring tumour uptake and background tissue levels in selected regions of interest on whole body images and (2) determining if suitable quantitative imaging metrics can be identified.
Evaluate safety of [I-124]-CPD-1028 Injection	Up to 30 days	The safety of \[I-124\]-CPD-1028 Injection will be assessed for up to 30 days post injection by measuring the occurrence of adverse events and changes from baseline in physical examination, clinical laboratory parameters, electrocardiogram recordings, and vital signs (blood pressure, heart rate, body temperature, respiratory rate and oxygen saturation).

Secondary Outcome Measures

Name	Time	Method
Measure blood and plasma clearance of [I-124]-CPD-1028 and levels of free [I-124]-Iodide	Up to 18 days	Blood and plasma clearance of \[I-124\]-CPD-1028 and levels of free \[I-124\]-iodide will be assessed by analysis of blood and plasma samples taken up to 18 days post-injection.
Compare [I-124]-CPD-1028 uptake in tumours to IGF-1R expression	Up to 18 days	\[I-124\]-CPD-1028 PET/CT images taken up to 18 days post-injection will be compared to immunohistochemistry staining scores of IGF-1R on previously obtained tumour samples.
Compare [I-124]-CPD-1028 PET/CT images to other imaging modalities	Up to 18 days	\[I-124\]-CPD-1028 PET/CT images taken up to 18 days post-injection will be visually (qualitatively) compared to previously obtained CT and/or MRI images.

Trial Locations

Locations (4)

Juravinski Cancer Centre; 🇨🇦 Hamilton, Ontario, Canada

University Health Network - Princess Margaret Cancer Centre; 🇨🇦 Toronto, Ontario, Canada

Sunnybrook Health Science Centre - Odette Cancer Centre; 🇨🇦 Toronto, Ontario, Canada

St. Joseph's Healthcare Hamilton; 🇨🇦 Hamilton, Ontario, Canada